Skip Menu

Stroke Clinical Trials at OhioHealth

Pioneering Stroke Treatments and Technologies

WE are a nationwide leader in research through our active participation in stroke clinical trials.

Because of the high volume of stroke patients we treat, OhioHealth Neuroscience Center at Riverside Methodist Hospital is able to pioneer leading-edge treatments and technologies through active participation in clinical trials. 

Stroke Clinical Trials at OhioHealth

Below are the stroke clinical trials in which we’re currently actively involved: 


ASSIST Registry Studying Various Operator Techniques

The purpose of this Registry is to assess the procedural success and clinical outcomes associated with various operator techniques for mechanical thrombectomy in large vessel occlusions (LVO).

Learn more at


Biomarkers of Acute Stroke Etiology in Clinic (BASIC)

The proposed study will investigate the clinical use of the ISCDX test that may differentiate between diverse stroke etiologies.

Learn more at


Coordinated, Collaborative, Comprehensive, Family-based, Integrated, Technology-enabled Stroke Care (C3FIT)

C3FIT will randomly assign 18 US hospital sites to continue Joint Commission-certified Comprehensive/Primary (CSC/PSC) design or to the novel Integrated Stroke Practice Unit (ISPU) design for stroke care. C3FIT's ISPU uses team-based, enhanced collaboration (called Stroke Central) and follows patients from presentation at the Emergency Department (ED) through 12-months post-discharge (called Stroke Mobile).  Results from C3FIT will provide high quality scientific evidence to determine the best stroke care design that ensures positive health for patients and caregivers.

Learn More at


EmboTrap® Revascularization Device Registry (EXCELLENT)

The objective of this study is to assess the efficacy of the EmboTrap® Revascularization Device in a real-world setting, as well as to explore correlations between patient comorbidities, clot characteristics, revascularization rates, and clinical outcomes.

Learn More at


Early Minimally-invasive Removal of IntraCerebral Hemorrhage (ICH) (ENRICH)

The purpose of this trial is to provide clinical evidence of functional improvement, safety, and economic benefit when comparing intracerebral hemorrhage (ICH) evacuation surgery to medical treatment.

Learn More at


Impact of Fever Prevention in Brain Injured Patients (INTREPID)

The purpose of this study is to assess fever burden and the impact on outcomes of fever prevention using the Arctic Sun 5000 Temperature Management System as compared to standard fever care in brain-injured patients.

Learn More at


pRESET for Occlusive Stroke Treatment (PROST)

To determine the safety and effectiveness of pRESET for the treatment of acute ischemic stroke within 8 hours of symptom onset (defined as time patient was last seen well) due to large vessel occlusion and to compare safety and effectiveness to the predicate device, Solitaire™ Platinum revascularization device.

Learn More at


Ruptured Aneurysms Treated with Hydrogel Coils (RAGE)

The purpose of this study is to determine the safety and occlusion rates when hydrogel coils are used in the treatment of ruptured intracranial aneurysms.

Learn More at


SELECT2: A Randomized Controlled Trial to Optimize Patient's Selection for Endovascular Treatment in Acute Ischemic Stroke

SELECT 2 is a prospective, randomized, international, multicenter, assessor-blinded controlled trial evaluating the efficacy and safety of thrombectomy in patients with large core on either CT or advanced perfusion imaging treated within 0-24 hours from last known well.

Learn More at


Tenecteplase in Stroke Patients Between 4.5 and 24 Hours (TIMELESS)

This study will evaluate the efficacy and safety of tenecteplase compared with placebo in patients with acute ischemic stroke (AIS).

Learn More at

Below are the endovascular & cardiac "stroke prevention" trials in which we’re currently actively involved: 


Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (CREST-2) Protocol

A set of two multicenter randomized trials that run in parallel – CEA in addition to intensive medical management (IMM) vs. intensive medical management alone OR CAS + IMM vs. IMM alone.

Learn More at


CREST 2 Registry (C2R)

A companion study to accompany CREST-2, this registry is for expansion of Medicare coverage for CAS to include procedures performed as part of C2R on symptomatic and asymptomatic patients beyond those categories covered under the 2005 CMS decision. Patients must either be excluded from or decline randomized trial CREST-2.

Learn More at


Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial - Hemodynamics (CREST-H)

CREST-H addresses the intriguing question of whether cognitive impairment can be reversed when it arises from abnormal cerebral hemodynamic perfusion in a hemodynamically impaired subset of the CREST-2 -randomized patients.

Learn More at


AMPLATZERTM PFO Occluder Post Approval Study (PFO PAS)

The purpose of this study is to confirm the safety and effectiveness of the AMPLATZERTM PFO Occluder in the post approval setting.  The AMPLATZERTM PFO Occluder is indicated for percutaneous, transcatheter closure of a PFO to reduce the risk of recurrent ischemic stroke in patients, who have had a cryptogenic stroke due to presumed paradoxical embolism.

Learn More at